ALSO NOTED: Human Genome Sciences to spin off CoGenesys; Nuvelo receives SPA from FDA; Voyager withdraws IPO; and much more...
Free newsletter via e-mail
> Human Genome Sciences will spin off CoGenesys, its early-stage drug development division. The independent company will focus on the early development of selected gene-based product opportunities. Report
> Nuvelo has received a Special Protocol Assessment (SPA) agreement from the FDA for its second Phase III trial of NAPA-3 for acute peripheral arterial occlusion (PAO), or "leg attack." Nuvelo's shares surged upon the news. Report
> Voyager Pharmaceutical has withdrawn its plans for an IPO. Report
> Maxygen has earned a $5 million milestone in its collaboration with Roche to develop interferon alpha protein therapies for hepatitis C and hepatitis B infections. Release
> Alnylam has advanced its pandemic flu project and will file an IND in early 2006. The company also announced that it has received federal funding for the program. Release
And Finally... A team of Stanford researchers have taught eight patients to "think their pain away." Article
SHARE
WITH: